Perinatal Opioid Exposure Primes the Peripheral Immune System Toward Hyperreactivity

Area of Science:

• Immunology
• Developmental Biology
• Pharmacology

Background:

• Opioid use during pregnancy is increasing, necessitating research into its effects on fetal development.
• Developmental opioid exposure can lead to immune priming, resulting in exaggerated immune responses and chronic inflammation.
• This study investigates the impact of perinatal methadone exposure on immune cell activation in a preclinical model.

Purpose of the Study:

• To investigate the consequences of developmental opioid exposure on the in vitro activation of peripheral blood mononuclear cells (PBMCs).
• To determine if methadone-exposed rat PBMCs exhibit altered baseline and stimulated cytokine and chemokine production compared to controls.
• To explore the potential for immune hyperreactivity as a consequence of prenatal opioid exposure.

Main Methods:

• Utilized a preclinical rat model of perinatal methadone exposure.
• Isolated pup peripheral blood mononuclear cells (PBMCs) on postnatal day 7 for in vitro culture.
• Assessed baseline and lipopolysaccharide (LPS)-stimulated cytokine and chemokine expression using multiplex electrochemiluminescence after 3 and 24 hours.

Main Results:

• Methadone-exposed PBMCs showed significantly increased baseline production of proinflammatory cytokines and chemokines (p < 0.0001).
• LPS stimulation resulted in a 3.5-fold increase in TNF-α and CXCL1 in methadone PBMCs after 3 hours (p < 0.0001).
• Sustained hyperreactivity was observed at 24 hours with increased TNF-α, CXCL1, IL-6, and IL-10 production in methadone PBMCs (p < 0.0001).

Conclusions:

• Developmental methadone exposure leads to increased baseline proinflammatory molecule production by PBMCs.
• Methadone-exposed PBMCs exhibit sustained hyperreactivity to immune stimulation, indicating immune priming.
• These findings suggest that prenatal opioid exposure can dysregulate immune responses, potentially impacting multiple organ systems, and highlight the utility of PBMC assays for biomarker development.